Cargando…

Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib

SIMPLE SUMMARY: Systemic therapy in advanced hepatocellular-carcinomas (HCC) has limited benefits, but some patients show partial responses (PR) and a few even a complete response (CR). Understanding the biological mechanisms could help clinicians in decision-making. Aim of this study was to develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombatto, Piero, Demirtas, Coskun Ozer, Ricco, Gabriele, Civitano, Luigi, Boraschi, Piero, Scalise, Paola, Cavallone, Daniela, Oliveri, Filippo, Romagnoli, Veronica, Bleve, Patrizia, Coco, Barbara, Salvati, Antonio, Urbani, Lucio, Bonino, Ferruccio, Brunetto, Maurizia Rossana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123288/ https://www.ncbi.nlm.nih.gov/pubmed/33922938 http://dx.doi.org/10.3390/cancers13092064

Ejemplares similares

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

The Circulating miRNA Profile of Chronic Hepatitis D and B Patients Is Comparable but Differs from That of Individuals with HBeAg-Negative HBV Infection
por: Cavallone, Daniela, et al.
Publicado: (2023)

Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine
por: Colombatto, Piero, et al.
Publicado: (2022)

A Serum MicroRNA Signature Is Associated with the Immune Control of Chronic Hepatitis B Virus Infection
por: Brunetto, Maurizia Rossana, et al.
Publicado: (2014)

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
por: Bonino, Ferruccio, et al.
Publicado: (2022)

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease
por: Yuan, Quan, et al.
Publicado: (2015)

Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?
por: Demirtas, Coskun Ozer, et al.
Publicado: (2021)

Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders
por: Demirtas, Coskun Ozer, et al.
Publicado: (2021)

Practicality and potential restrictions of unresectable hepatocellular carcinoma prognostic index
por: Demirtas, Coskun Ozer, et al.
Publicado: (2022)

Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis
por: De Rosa, Laura, et al.
Publicado: (2022)

Circulating Hepatitis B Surface Antigen Particles Carry Hepatocellular microRNAs
por: Novellino, Luisa, et al.
Publicado: (2012)

Thermal Care of Functional Dyspepsia Based on Bicarbonate-Sulphate-Calcium Water: A Sequential Clinical Trial
por: Rocca, Giuseppe, et al.
Publicado: (2007)

Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease
por: Rebelos, Eleni, et al.
Publicado: (2021)

T cell receptor-therapy in HBV-related hepatocellularcarcinoma
por: Bertoletti, Antonio, et al.
Publicado: (2015)

Case Report: MIS-C With Prominent Hepatic and Pancreatic Involvement in a Vaccinated Adolescent – A Critical Reasoning
por: Consolini, Rita, et al.
Publicado: (2022)

Evidence of a Gastro-Duodenal Effect on Adipose Tissue and Brain Metabolism, Potentially Mediated by Gut–Liver Inflammation: A Study with Positron Emission Tomography and Oral (18)FDG in Mice
por: Guzzardi, Maria Angela, et al.
Publicado: (2022)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Maternal High-Fat Feeding Affects the Liver and Thymus Metabolic Axis in the Offspring and Some Effects Are Attenuated by Maternal Diet Normalization in a Minipig Model
por: La Rosa, Federica, et al.
Publicado: (2021)

An E-Nose for the Monitoring of Severe Liver Impairment: A Preliminary Study
por: Germanese, Danila, et al.
Publicado: (2019)

Exploring the Outcome of Disappearance or Small Remnants of Colorectal Liver Metastases during First-Line Chemotherapy on Hepatobiliary Contrast-Enhanced and Diffusion-Weighted MR Imaging
por: Boraschi, Piero, et al.
Publicado: (2023)

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity
por: Yoshioka, Naoki, et al.
Publicado: (2019)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval Confluence
por: Urbani, Lucio, et al.
Publicado: (2015)

Maturation of the Visceral (Gut-Adipose-Liver) Network in Response to the Weaning Reaction versus Adult Age and Impact of Maternal High-Fat Diet
por: Guzzardi, Maria Angela, et al.
Publicado: (2021)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
por: Marcellin, Patrick, et al.
Publicado: (2012)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Urgent Liver Transplantation Soon After Recovery From COVID‐19 in a Patient With Decompensated Liver Cirrhosis
por: Martini, Silvia, et al.
Publicado: (2020)

Side-branch intraductal papillary mucinous neoplasms of the pancreas: outcome of MR imaging surveillance over a 10 years follow-up
por: Boraschi, Piero, et al.
Publicado: (2020)

Predictive Power of Tissue and Circulating Biomarkers for the Severity of Biopsy-Validated Chronic Liver Diseases
por: Bocci, Guido, et al.
Publicado: (2022)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2018)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
por: Nix, Ryan, et al.
Publicado: (2019)

Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
por: Hong, Young Mi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ldfd8e364s5u5qauj20io93531